Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone416-595-0627
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/13/2019 (Estimated)
OptionableOptionable
Trillium Therapeutics (NASDAQ:TRIL) Frequently Asked Questions
What is Trillium Therapeutics' stock symbol?
Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."
How were Trillium Therapeutics' earnings last quarter?
Trillium Therapeutics Inc (NASDAQ:TRIL) announced its earnings results on Tuesday, August, 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.37) by $0.19. The biotechnology company earned $0.03 million during the quarter. View Trillium Therapeutics' Earnings History.
When is Trillium Therapeutics' next earnings date?
What price target have analysts set for TRIL?
2 Wall Street analysts have issued 12-month price objectives for Trillium Therapeutics' stock. Their forecasts range from $4.00 to $4.00. On average, they expect Trillium Therapeutics' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 1,328.6% from the stock's current price. View Analyst Price Targets for Trillium Therapeutics.
What is the consensus analysts' recommendation for Trillium Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trillium Therapeutics.
Has Trillium Therapeutics been receiving favorable news coverage?
News headlines about TRIL stock have been trending somewhat negative on Wednesday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Trillium Therapeutics earned a coverage optimism score of -1.2 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Trillium Therapeutics.
Are investors shorting Trillium Therapeutics?
Trillium Therapeutics saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 37,200 shares, a decline of 90.0% from the August 30th total of 372,000 shares. Based on an average daily volume of 232,400 shares, the short-interest ratio is presently 0.2 days. Approximately 0.2% of the shares of the company are short sold. View Trillium Therapeutics' Current Options Chain.
Who are some of Trillium Therapeutics' key competitors?
Some companies that are related to Trillium Therapeutics include Clearside Biomedical (CLSD), Acer Therapeutics (ACER), Addex Therapeutics (ADDXF), Zosano Pharma (ZSAN), Fibrocell Science (FCSC), Akari Therapeutics (AKTX), Alimera Sciences (ALIM), Leap Therapeutics (LPTX), ContraFect (CFRX), Zafgen (ZFGN), DiaMedica Therapeutics (DMAC), Aptevo Therapeutics (APVO), Intec Pharma (NTEC), Provectus Biopharmaceuticals (PVCT) and Acerus Pharmaceuticals (TRLPF).
What other stocks do shareholders of Trillium Therapeutics own?
Who are Trillium Therapeutics' key executives?
Trillium Therapeutics' management team includes the folowing people:
- Dr. Bjorn Johan Niclas Stiernholm, Pres, CEO & Director
- Mr. James T. Parsons C.A., C.P.A., MAcc, CPA-CA, Chief Financial Officer (Age 54)
- Dr. Robert Uger, Chief Scientific Officer
- Dr. Penka Petrova, Chief Devel. Officer
- Dr. Yaping Shou, Chief Medical Officer
How do I buy shares of Trillium Therapeutics?
Shares of TRIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Trillium Therapeutics' stock price today?
One share of TRIL stock can currently be purchased for approximately $0.28.
How big of a company is Trillium Therapeutics?
What is Trillium Therapeutics' official website?
How can I contact Trillium Therapeutics?
Trillium Therapeutics' mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The biotechnology company can be reached via phone at 416-595-0627 or via email at [email protected]
MarketBeat Community Rating for Trillium Therapeutics (NASDAQ TRIL)
MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe TRIL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRIL will underperform the S&P 500 over the long term. You may vote once every thirty days.
